In a world where proximity, travel, and climate change give rise to increasing incidences and rapidly spreading infectious diseases, the COVID-19 pandemic reminded us how important it is to tackle infectious diseases through both prevention and treatment. To stay ahead of this evolutionary arms race, we need to invest preemptively in innovative platforms that can provide solutions to current infectious diseases and respond to outbreaks with speed and agility.

Diseases like COVID-19 disproportionately impact and threaten immunocompromised populations, which respresent 3% of the population. There are many reasons people may fall into this category, including cancer treatments, organ transplants, immunosuppressive therapies, and immunodeficiencies. These people remain vulnerable despite vaccinations – they need better protection both now and in the future.

ExeVir is doing its part to tackle the growing impact of infectious diseases by building a progressive pipeline of therapies that will help protect and treat the most vulnerable patients in our societies: